- No file added yet -

Time flow of the different experimental settings.

figure

posted on 2016-10-20, 17:59 authored by Felix Ulbrich, Kai B. Kaufmann, Alexander Meske, Wolf A. Lagrèze, Michael Augustynik, Hartmut Buerkle, Carlos C. Ramao, Julia Biermann, Ulrich Goebel

First row: Fluorogold (FG) labeling seven days prior to IRI, subsequent treatment with or without p38 inhibitor (SB203580) and/or iALF-186/ALF-186 and enucleation another seven days later, giving FG the chance to promote into RGC via axonal transport. Second row: IRI with or without p38 inhibitor (SB203580) and/or iALF-186/ALF-186 treatment and enucleation 24 or 48 hours after IRI for molecular analysis. Third row: IRI with or without p38 inhibitor (SB203580) and/or iALF-186/ALF-186 treatment and enucleation 24 or 48 hours after IRI for immunohistochemical analysis.